Stock to Watch Abraxis Bioscience Inc. Announces their Latest News

Join today and be part of the best free investment newsletter on the web where we focus on market moving news.

Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, announces it will release its 2009 fourth quarter financial results before the market opens on Thursday, March 11, 2010. The company also said that senior management will host an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET to review the company’s financial results.

The conference call will be presented to interested parties through a live audio webcast at and www.earnings.com. The call will also be archived and accessible at both sites for six months.

About Abraxis:

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company’s product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioSciences other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. It has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; and ProMetic Life Sciences Inc. Abraxis BioScience also has licensing agreements with Green Cross Corporation and University of Southern California. The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis Bioscience, Inc. in November 2007. Abraxis BioScience is based in Los Angeles, California.

You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com .Gerard@WallStreetGrand.com

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.

Disclaimer:

Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer click the link http://www.wallstreetgrand.com/disclosure.html.